Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Live News EQUITY FLASH M impact Oct 12, 2026, 04:45 PM UTC

Nasdaq Composite Falls 90.06 Points (0.33%)

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

QQQ

Related stories

Analysts Issue Mixed Delta Price-Target Revisions After Q3 Results BMO Capital raised its Delta price target to $105 from $100 and maintained an Outperform rating. The report also notes mixed analyst revisions. M impact | EQUITY | Oct 12, 2026, 06:04 PM UTC US session market picture: S&P 500 -0.08%, Nasdaq 100 -0.7%; EUR/USD -0.39%, WTI +2.14%, WBD leads volume US session market picture. US index futures: S and P futures is down 0.08 percent, Nasdaq futures is down 0.7 percent, Dow futures is up 0.36 percent and Russell futures is down 0. M impact | EQUITY | Oct 12, 2026, 06:02 PM UTC Disney executives to discuss FY and Q4 2026 results via webcast The company announced a webcast discussion of its fiscal full-year and fourth-quarter 2026 financial results. M impact | EQUITY | Oct 12, 2026, 05:51 PM UTC S&P 1500 Pension Funding Level Rose 1 Point to 113% in September Marsh estimated that pension plans sponsored by S&P 1500 companies were 113% funded at September-end, up 1 percentage point. Higher discount rates drove the increase, slightly offs M impact | EQUITY | Oct 12, 2026, 05:46 PM UTC JPMorgan Q3 Revenue and Earnings Seen Growing JPMorgan shares rose 0.4% Monday ahead of its quarterly report, due before Tuesday's market open. Wall Street expects adjusted EPS of $5.90 versus $5.07 a year earlier and revenue M impact | EQUITY | Oct 12, 2026, 05:45 PM UTC Regeneron Reports No New Abnormal Bone Growth in Extended Trial Patients showed no new abnormal bone growth in an extended Phase 3 trial of Regeneron’s recently approved rare disease drug. REGN shares rose about 2.8%, heading for their best day M impact | EQUITY | Oct 12, 2026, 05:41 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.